- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06552520
Evaluar el ensayo clínico de fase III de la inyección de TQH2722 en el tratamiento de la dermatitis atópica de moderada a grave
Un ensayo clínico de fase III multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de la inyección de TQH2722 en el tratamiento de la dermatitis atópica de moderada a grave en sujetos
This is a randomized, double-blind, placebo-controlled clinical trial with 500 participants. In this study, the safety evaluation used the common toxic reaction criteria of the National Cancer Institute to evaluate the adverse events of the drugs, and the effectiveness evaluation used the eczema area and severity score and the overall investigator score to confirm the efficacy.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Anhui
-
Bengbu, Anhui, Porcelana, 233004
- The First Affiliated Hospital of Bengbu Medical College
-
Tongling, Anhui, Porcelana, 244000
- Tongling People's Hospital
-
Wuhu, Anhui, Porcelana, 241000
- The Second Affiliated Hospital of Wannan Medical College
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Porcelana, 100050
- Beijing Friendship Hospital, Capital Medical University
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Porcelana, 400010
- The First Affiliated Hospital of Chongqing Medical University
-
Chongqing, Chongqing Municipality, Porcelana, 400038
- The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University
-
Chongqing, Chongqing Municipality, Porcelana, 400072
- The Second Affiliated Hospital of Chongqing Medical University
-
Chongqing, Chongqing Municipality, Porcelana, 404100
- Chongqing Three Gorges Medical College affiliated People's Hospital
-
-
Fujian
-
Xiamen, Fujian, Porcelana, 361021
- The Second Affiliated Hospital of Xiamen Medical College
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana, 510000
- Dermatology Hospital of Southern Medical UniversityDermatology Hospital of Southern Medical University
-
Guangzhou, Guangdong, Porcelana, 510000
- The Second Affiliated Hospital of Guangzhou Medical University
-
Shenzhen, Guangdong, Porcelana, 518036
- Peking University Shenzhen Hospital
-
-
Guangxi
-
Liuzhou, Guangxi, Porcelana, 545006
- Liuzhou People's Hospital
-
-
Hebei
-
Cangzhou, Hebei, Porcelana, 061012
- Cangzhou Central Hospital
-
Chengde, Hebei, Porcelana, 067000
- The Affiliated Hospital of Chengde Medical College
-
-
Heilongjiang
-
Harbin, Heilongjiang, Porcelana, 150036
- Heilongjiang Provincial Hospital
-
Harbin, Heilongjiang, Porcelana, 151100
- The Second Affiliated Hospital of Harbin Medical University
-
Qiqihar, Heilongjiang, Porcelana, 161005
- Qiqihar Hospital of Traditional Chinese Medicine
-
-
Henan
-
Anyang, Henan, Porcelana, 455001
- Anyang District Hospital, Puyang City
-
Luoyang, Henan, Porcelana, 471000
- The Second Affiliated Hospital of Henan University of Science and Technology
-
Nanyang, Henan, Porcelana, 473000
- Nanyang city first People's Hospital
-
Sanmenxia, Henan, Porcelana, 472000
- Sanmenxia Central Hospital
-
Zhengzhou, Henan, Porcelana, 450000
- Henan Provincial People's Hospital
-
Zhengzhou, Henan, Porcelana, 471000
- The First Affiliated Hospital of Henan University of Science and Technology
-
-
Hubei
-
Jingzhou, Hubei, Porcelana, 434000
- Jingzhou Central Hospital
-
Wuhan, Hubei, Porcelana, 430060
- Wuhan University People's Hospital
-
Yichang, Hubei, Porcelana, 443003
- Yichang Central People's Hospital
-
-
Hunan
-
Changsha, Hunan, Porcelana, 410013
- Xiangya Third Hospital, Central South University
-
Changsha, Hunan, Porcelana, 410011
- The Second Xiangya Hospital, Central South University
-
Hengyang, Hunan, Porcelana, 421001
- The First Affiliated Hospital of University of South China
-
Huaihua, Hunan, Porcelana, 418000
- Hunan Medical University General Hospital
-
-
Inner Mongolia
-
Baotou, Inner Mongolia, Porcelana, 14017
- The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
-
Baotou, Inner Mongolia, Porcelana, 14040
- Baotou Central Hospital
-
Hohhot, Inner Mongolia, Porcelana, 10000
- Affiliated Hospital of Inner Mongolia Medical University
-
-
Jiangsu
-
Changzhou, Jiangsu, Porcelana, 213000
- Changzhou First People's Hospital
-
Suzhou, Jiangsu, Porcelana, 215000
- The Second Affiliated Hospital of Soochow University
-
Suzhou, Jiangsu, Porcelana, Weiling
- Suzhou Municipal Hospital
-
Xuzhou, Jiangsu, Porcelana, 221132
- Affiliated Hospital of Xuzhou Medical University
-
Yancheng, Jiangsu, Porcelana, 224005
- Yancheng First People's Hospital
-
Zhenjiang, Jiangsu, Porcelana, 210039
- Affiliated Hospital of Jiangsu University
-
-
Jiangxi
-
Nanchang, Jiangxi, Porcelana, 330006
- The Second Affiliated Hospital of Nanchang University
-
-
Jilin
-
Changchun, Jilin, Porcelana, 130041
- Second Hospital of Jilin University
-
-
Liaoning
-
Panjin, Liaoning, Porcelana, 124120
- Panjin Liao oil precious stone flower hospital
-
-
Ningxia
-
Yinchuan, Ningxia, Porcelana, 750010
- Yinchuan First People's Hospital
-
-
Qinghai
-
Xining, Qinghai, Porcelana, 810000
- Affiliated Hospital of Qinghai University
-
-
Shandong
-
Dezhou, Shandong, Porcelana, 277102
- Dezhou People's Hospital
-
Jinan, Shandong, Porcelana, 250012
- Shandong University Qilu Hospital
-
Liaocheng, Shandong, Porcelana, 252000
- Liaocheng People's Hospital
-
Yantai, Shandong, Porcelana, 264000
- Yantai Yuhuangding Hospital
-
Zaozhuang, Shandong, Porcelana, 277102
- Zaozhuang Municipal Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana, 545006
- Shanghai Dermatology Hospital
-
-
Shanxi
-
Baoji, Shanxi, Porcelana, 721008
- Baoji Central Hospital
-
Taiyuan, Shanxi, Porcelana, 030000
- Shanxi Provincial People's Hospital
-
Taiyuan, Shanxi, Porcelana, 030009
- Peking University First Hospital Taiyuan Hospital
-
Xi’an, Shanxi, Porcelana, 710004
- The Second Affiliated Hospital of Xi 'an Jiaotong University
-
Xi’an, Shanxi, Porcelana, 710032
- The First Affiliated Hospital of PLA Air Force Medical University
-
Xi’an, Shanxi, Porcelana, 710032
- The First Affiliated Hospital of Xi 'an Medical College
-
Xi’an, Shanxi, Porcelana, 710032
- The Second Affiliated Hospital of the Chinese People's Liberation Army Air Force Medical University
-
-
Sichuan
-
Chengdu, Sichuan, Porcelana, 610000
- Sichuan Provincial People's Hospital
-
Chengdu, Sichuan, Porcelana, 610000
- Chengdu Second People's Hospital
-
Chengdu, Sichuan, Porcelana, 610072
- Chengdu Second People's Hospital
-
Luzhou, Sichuan, Porcelana, 646000
- Affiliated Hospital of Southwest Medical University
-
Suining, Sichuan, Porcelana, 629000
- Suining Central Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Porcelana, 300120
- Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
-
Tianjin, Tianjin Municipality, Porcelana, 300190
- Tianjin First Central Hospital
-
-
Xinjiang
-
Ürümqi, Xinjiang, Porcelana, 830002
- People's Hospital of Xinjiang Uygur Autonomous Region
-
Ürümqi, Xinjiang, Porcelana, 830002
- Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
-
-
Yunnan
-
Kunming, Yunnan, Porcelana, 650032
- The First Affiliated Hospital of Kunming Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, Porcelana, 310006
- Hangzhou First People's Hospital
-
Hangzhou, Zhejiang, Porcelana, 310009
- Hangzhou Third People's Hospital
-
Jiaxing, Zhejiang, Porcelana, 545006
- Jiaxing second Hospital
-
Jinhua, Zhejiang, Porcelana, 321000
- Jinhua Central Hospital
-
Ningbo, Zhejiang, Porcelana, 315211
- The First Affiliated Hospital of Ningbo University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- The age of signing the informed consent is 18-75 years old, regardless of gender.
- Meet the 2014 American Academy of Dermatology (AAD) standards, diagnosed as AD.
- During screening and baseline visit, eczema area and severity score (EASI) ≥16 points; Investigator global score (IGA) ≥3 points; Affected body surface area (BSA) ≥10%; Baseline pruritus Peak Value Scale (NRS) weekly mean ≥4 points.
- Have received at least 4 weeks of moderate-to-strong action or at least 2 weeks of super effective external glucocorticoid (TCS) treatment or sufficient duration of systemic glucocorticoid treatment, the efficacy is not sufficient; Or subjects cannot receive the above treatment due to adverse reactions or potential risks.
Exclusion Criteria:
- Used immunosuppressants/immunomodulatory drugs, ultraviolet phototherapy, systemic Chinese medicine treatment within 4 weeks before randomization.
- Received topical calcineurin inhibitors (TCS), topical calcineurin inhibitors (TCI), and other topical preparations within 2 weeks before randomization.
- Received anti-interleukin-4 receptor alpha (IL-4R) monoclonal antibodies, anti-ige monoclonal antibodies, or other biologic agents within 12 weeks or 5 half-lives (whichever is longer) prior to randomization.
- Had received live attenuated vaccine within 12 weeks prior to randomization or planned to receive it during the study period.
- Use of antihistamines within 1 week prior to randomization (unless you have received steady doses of antihistamines for at least 7 days).
- Received allergen specific immunotherapy within 6 months before randomization.
- There are skin comorbidities that may interfere with study evaluation.
- There is a history of clinically significant illness that the investigator believes poses a risk to the safety of the subject and is poorly controlled.
- A known or suspected history of immunosuppression (immune deficiency).
- Subjects with any type of active malignancy or a history of malignancy (except cervical cancer or non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and papillary thyroid carcinoma that have been cured for more than 5 years prior to the screening period).
- Subject may have active Mycobacterium tuberculosis infection.
- Subjects with severe liver and kidney function impairment.
- Screening period HIV antibody positive, or have a history of HIV infection.
- Screening period of treponema pallidum antibody positive.
- Participated in clinical trials of other drugs or medical devices within 12 weeks prior to randomization.
- Treatment-requiring infections were present in the 4 weeks prior to randomization.
- During the study period, subjects plan to undergo major surgical operations.
- Pregnant or lactating women.
- Alcohol, drug abuse and known drug dependence.
- History of atopic keratoconjunctivitis with corneal involvement.
- The subject has any medical or psychiatric symptoms that interfere with participation in the study or with the interpretation of the study results.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: TQH2722 injection
TQH2722 injection, 14 days for a treatment cycle |
Humanized interleukin-4 receptor alpha (4Rα) monoclonal antibody |
|
Comparador de placebos: Placebo of TQH2722 injection
Placebo of TQH2722 injection, 14 days for a treatment cycle |
Placebo without drug substance |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Participants who achieved EASI-75 (≥75% improvement from baseline) on the eczema Area and Severity score (EASI)
Periodo de tiempo: Baseline to 16 weeks after treatment
|
Percentage of participants who achieved EASI-75 (≥75% improvement from baseline) on the eczema Area and Severity score (EASI) |
Baseline to 16 weeks after treatment
|
|
Subjects with an Investigator's Overall Rating (IGA) score (5-scale) of 0 or 1 and ≥2 points decline from baseline
Periodo de tiempo: Baseline to 16 weeks after treatment
|
Percentage of subjects with an Investigator's Overall Rating (IGA) score (5-scale) of 0 or 1 and ≥2 points decline from baseline. |
Baseline to 16 weeks after treatment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The incidence of adverse events
Periodo de tiempo: After medication to 60 weeks
|
Adverse events that occur during treatment |
After medication to 60 weeks
|
|
Steady valley concentration of TQH2722
Periodo de tiempo: After medication to 60 weeks
|
Relatively stable concentration levels of TQH2722 |
After medication to 60 weeks
|
|
The incidence and titer of drug-resistant antibodies (ADA) in subjects
Periodo de tiempo: After medication to 60 weeks
|
The incidence and titer of drug-resistant antibodies (ADA) in subjects |
After medication to 60 weeks
|
|
Incidence of neutralizing antibodies (Nab)
Periodo de tiempo: After medication to 60 weeks
|
Incidence of neutralizing antibodies (Nab) |
After medication to 60 weeks
|
|
Eczema area and severity score (EASI) change from baseline
Periodo de tiempo: From baseline to week 60
|
The affected area of each site was assessed. According to the percentage of the affected area, the corresponding Region score was 0 to 6. The higher the score, the more severe the involvement. |
From baseline to week 60
|
|
Rate of change from baseline in the Investigator's overall Score (IGA)
Periodo de tiempo: After medication to 60 weeks
|
The researchers assessed the form of the dermatitis using a 5-point scale (0-5), with higher scores being more severe. |
After medication to 60 weeks
|
|
Change of body surface area from baseline in moderate to severe atopic dermatitis
Periodo de tiempo: After medication to 60 weeks
|
The researchers used a nine-point scale to assess the percentage of AD affected area in the whole body (0-100%), with the larger the value, the more severe the involvement. |
After medication to 60 weeks
|
|
Change rate of atopic dermatitis score (SCORAD) from baseline
Periodo de tiempo: After medication to 60 weeks
|
According to the involvement of skin surface area, the severity of skin lesions and the subjective symptom score, the higher the value, the more severe the dermatitis. |
After medication to 60 weeks
|
|
Change in daily Peak Itch Digital Rating Scale (NRS) score from baseline
Periodo de tiempo: After medication to 60 weeks
|
Rate the most severe itching in the past 24 hours on a scale of 0-10, with higher numbers being more severe. |
After medication to 60 weeks
|
|
Rate of change in dermatological quality of life (DLQI) score from baseline
Periodo de tiempo: After medication to 60 weeks
|
Assess how much the skin problems of the last week have affected the subjects' lives |
After medication to 60 weeks
|
|
Change in patients' self-assessment of eczema (POEM) from baseline
Periodo de tiempo: After medication to 60 weeks
|
The number of days in the past 7 days to assess whether eczema caused skin problems such as itching and bleeding, 0 indicates no days, 1 indicates 1-2 days, 2 indicates 3-4 days, 3 indicates 5-6 days, and 4 indicates all days. |
After medication to 60 weeks
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades Genéticas Congénitas
- Enfermedades del sistema inmunológico
- Hipersensibilidad, Inmediata
- Hipersensibilidad
- Enfermedades de la piel
- Enfermedades De La Piel Genéticas
- Enfermedades De La Piel Eccematosas
- Dermatitis
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Enfermedades de la piel y del tejido conectivo
- Dermatitis Atópica
Otros números de identificación del estudio
- TQH2722-III-01
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .